Search Result
Results for "
tomography
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-W100209
-
|
|
Potassium Channel
|
Others
|
|
5Me3F4AP is a potent blocker of potassium channel, with the IC50 of 220 μM to 693 μM when the pH is increased from 6.4 to 9.1. 5Me3F4AP has the potential to cross the blood-brain barrier and potential application in positron emission tomography (PET) .
|
-
-
- HY-149766
-
|
|
HDAC
|
Neurological Disease
|
|
PB94 is a selective HDAC11 inhibitor (IC50=108 nM). PB94 can be radiolabeled as [11C]-PB94 for use in positron emission tomography (PET), as well as brain uptake and metabolic properties in administered live animals. PB94 improves neuropathic pain in mice and could be used to study neurological indications .
|
-
-
- HY-117756
-
|
DCFPYL
|
PSMA
|
Others
Cancer
|
|
Piflufolastat (DCFPYL) can be used to the preparation of piflufolastat F 18 (DCFPyL F-18). piflufolastat F 18. Piflufolastat F-18 is an 18F-labelled diagnostic imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) that targets prostate-specific membrane antigen (PSMA) .
|
-
-
- HY-119190
-
|
|
Phosphodiesterase (PDE)
|
Neurological Disease
|
|
PF-06445974, a promising positron emission tomography (PET) lead, has exquisite potency at PDE4B with an IC50 <1 nM. The IC50 values are 36, 4.7 and 17 nM for PDE4D, PDE4A and PDE4C, respectively. PF-06445974 has good selectivity over PDE4D, excellent brain permeability, and a high level of specific binding in the "cold tracer" study .
|
-
-
- HY-158317
-
|
|
CXCR
Biochemical Assay Reagents
|
Others
|
|
SFB-AMD3465 is an AMD3465 (HY-15971A) derivative. SFB-AMD3465 is utilized as positron emission tomography (PET) tracer for CXCR4, when labeled with radioactive Fluorine .
|
-
-
- HY-160607
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Others
|
|
MMA-NODAGA is a chelator for site-specific labeling of targeting proteins containing unpaired cysteine. MMA-NODAGA can be used to conjugate with exosome and 64Cu in image with positron emission tomography (PET) <[2].
|
-
-
- HY-152152
-
|
|
MAGL
|
Neurological Disease
|
|
JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 392 nM. JZP-MA-13 shows no inhibition of MAGL, ABHD12, FAAH, or other serine hydrolases. JZP-MA-13 is a positron emission tomography (PET) ligand for in vivo imaging of the ABHD6 .
|
-
-
- HY-W728451
-
|
|
FAAH
|
Cardiovascular Disease
Neurological Disease
|
|
URB694 is a carbamate FAAH inhibitor that irreversibly carbamoylate the nucleophile catalytic serine in FAAH active site. URB694 exhibits antidepressant-like activity and cardioprotective effects. URB694 can be used to prepare 11C-Carbonyl-URB694 for in vivo positron emission tomography (PET) imaging studies of the brain FAAH .
|
-
-
- HY-106586
-
|
P-286
|
Biochemical Assay Reagents
|
Others
|
|
Ioxaglic acid (P-286) is negatively charged contrast agent, is useful as an inverse indicator for glycosaminoglycan (GAG) used in computed tomography (CT). Ioxaglic acid can be used for imaging of human osteoarthritic cartilage via quantitative assessment of glycosaminoglycan content .
|
-
-
- HY-146180
-
|
|
FAP
|
Cancer
|
|
FSDD0I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD0I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging .
|
-
-
- HY-146181
-
|
|
FAP
|
Cancer
|
|
FSDD1I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD1I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging .
|
-
-
- HY-146182
-
|
|
FAP
|
Cancer
|
|
FSDD3I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD3I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging .
|
-
-
- HY-106244
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-106244A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-139048
-
|
|
iGluR
|
Neurological Disease
|
|
Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
|
-
-
- HY-139048A
-
|
|
iGluR
|
Neurological Disease
|
|
Fluoroethylnormemantine hydrochloride, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine hydrochloride can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine hydrochloride exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
|
-
-
- HY-146102
-
|
|
mAChR
|
Others
|
|
M1 ligand 1 (compound 3b-b) is a muscarinic acetylcholine receptor M1 ligand. M1 ligand 1 is a N-desmethyl congener of arecoline derivative. M1 ligand 1 can be used as PET (positron emission tomography) radiotracer .
|
-
-
- HY-75706
-
|
|
PARP
Ligands for Target Protein for PROTAC
|
Cancer
|
|
N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a PARP inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .
|
-
-
- HY-101184
-
-
-
- HY-128890B
-
|
|
ADC Linker
Biochemical Assay Reagents
|
Cancer
|
|
DOTA-NHS-ester (TFA) is used as a linker for affibody molecules, and it can be employed in small animal positron emission tomography (PET), single photon emission computed tomography (SPECT), and CT scanning. DOTA-NHS-ester can be used to label radiotracers or imaging probes for tumor detection .
|
-
-
- HY-P10220
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Biochemical Assay Reagents
|
Others
|
|
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography . NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-152148
-
|
|
MAGL
|
Neurological Disease
|
|
JZP-MA-11 is a positron emission tomography (PET) ligand targeting the endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC50 value of 126 nM. JZP-MA-11 can cross the blood-brain barrier (BBB). [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate (NHP) .
|
-
-
- HY-136873
-
-
-
- HY-159001
-
|
|
Biochemical Assay Reagents
|
Others
|
|
ZCDD083 can be used as a positron emission tomography (PET) tracer for atherosclerotic plaques imagination, when labeled with 18F isotope .
|
-
-
- HY-101186
-
MK-6240
1 Publications Verification
|
Tau Protein
|
Neurological Disease
|
|
MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs .
|
-
-
- HY-B0594S
-
|
|
Isotope-Labeled Compounds
Autophagy
Mitophagy
|
Cancer
|
|
Iohexol-d5 is deuterium labeled Iohexol. Iohexol is a radiographic contrast agent and can be applied for myelography, computerized tomography (cisternography, ventriculography) and MicroCT imaging in vivo[1].
|
-
-
- HY-129059
-
|
NNC 756
|
Dopamine Receptor
|
Neurological Disease
|
|
Odapipam (NNC 756) is a selective, high affinity and benzazepine dopamine D1 receptor antagonist with a Kd of 0.18 nM. Odapipam is also a superior positron emission tomography (PET) radiotracer .
|
-
-
- HY-147173
-
|
|
FAP
|
Cancer
|
|
FAPI-74 is a PET (positron emission tomography) tracer targeting the fibroblast activation protein (FAP). FAPI-74 can be used for FAP-positive tumor research .
|
-
-
- HY-111514
-
-
-
- HY-135497
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
Fallypride is a potent antagonist of dopamine D2/D3 receptor. Fallypride, in the form of fallypride ( 18F), can be used as a positron emission tomography (PET) radiotracer .
|
-
-
- HY-163831
-
|
|
mGluR
|
Neurological Disease
|
|
AZ12559322 is a positive allosteric modulator of mGluR2, with the Ki value of 1.31 nM. AZ12559322 can be used in neurological research .
|
-
-
- HY-103326
-
|
|
Cannabinoid Receptor
|
Neurological Disease
|
|
NIDA-41020 is a potent and selective cannabinoid receptor 1(CB1) antagonist with a Ki of 4.1 nM. NIDA-41020 was designed as a potential radioligand for use in positron emission tomography (PET) .
|
-
-
- HY-D2334
-
|
|
Radionuclide-Drug Conjugates (RDCs)
HSP
|
Cancer
|
|
AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .
|
-
-
- HY-167899
-
|
|
mGluR
|
Neurological Disease
|
|
PXT-012253 is a positron emission tomography (PET) ligand for mGluR4, as it binds to an allosteric site on mGluR4. PXT-012253 can be utilized in researches related to Parkinson's disease and levodopa-induced dyskinesia .
|
-
-
- HY-163545
-
|
|
Others
|
Cancer
|
|
Tc-Me2P is a 99MTC-labeled acrylamide (PnAO) derivative that contains two 4-methyl-2-nitroimidazole groups. The primary activity of Tc-Me2P is as an imaging agent for tumor hypoxia. By specifically binding to hypoxic regions in tumor tissue, it can be used for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging to detect hypoxia in tumors. Tc-Me2P can be used to study the targeting of different chemical structures in tumors and normal tissues .
|
-
-
- HY-B0594
-
Iohexol
3 Publications Verification
|
Autophagy
Mitophagy
|
Cancer
|
|
Iohexol is a non-ionic, water-soluble contrast agent used as a reference marker for the determination of glomerular filtration rate (GFR) at the level of renal function. Iohexol can be used for contrast in myelography, computerized tomography (cisternography, ventriculography) and MicroCT imaging .
|
-
-
- HY-153549
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Others
|
|
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-P10744
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-P5053
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Integrin
|
Cancer
|
|
Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α?β? selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-117502
-
|
|
Monoamine Oxidase
|
Others
|
|
SL-25.1188 is a potent monoamine oxidase B (MAO-B) inhibitor with Ki values of 2.9 and 8.5 nM for human MAO-B and rat MAO-B, respectively. SL-25.1188 can be used for positron emission tomography .
|
-
-
- HY-101185
-
|
|
Tau Protein
|
Neurological Disease
|
|
T808 is a tau-selective Alzheimer’s PET ligand. T808 is a type of imaging agent used in positron emission tomography (PET) scans. It is a radiotracer that is used to help visualize certain areas of the body, such as the brain, in order to diagnose and monitor various medical conditions .
|
-
-
- HY-158243
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
Fallypride precursor (Compound 15) can be used for synthesis of Fallypride (HY-135497). Fallypride is an antagonist of the dopamine D2/D3 receptor. Fallypride can be used as a positron emission tomography (PET) radiotracer when labeled with 18F .
|
-
-
- HY-126226
-
|
|
Others
|
Cancer
|
|
MK-6240 Precursor (6e) is the synthetic precursor of (18)F]-MK-6240. (18)F]-MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs .
|
-
-
- HY-153248
-
|
|
Others
|
Others
|
|
PBR28 is an TSPO modulator, which can be used for prevention research of Pulmonary Arterial Hypertension (PAH). PBR28 can be used to trace 18 KDa transporter (TSPO) by adding radioactive labeling, which plays an important role in brain positron emission tomography (PET) imaging studies .
|
-
-
- HY-141899
-
|
|
mAChR
|
Neurological Disease
|
|
MK-6884 is a M4 muscarinic receptor positive allosteric modulator (PAM) with a Ki value of 0.19 nM. MK-6884 can be used for the research of the neurodegenerative diseases. MK-6884 can be conveniently radiolabeled with carbon-11 and as a positron emission tomography (PET) imaging agent .
|
-
-
- HY-160116
-
|
|
α-synuclein
|
Neurological Disease
|
|
α-Synuclein aggregate binder 1 (Compound C05-05) is a collective binder and an inhibitor for α-synuclein aggregation. α-Synuclein aggregate binder 1 is utilized in Positron Emission Tomography (PET) imaging and fluorescence microscope, that can diagnose and ameliorate the neurodegenerative disease .
|
-
-
- HY-120947
-
|
|
Drug Intermediate
|
Neurological Disease
|
|
AV-105 is a Florbetapir ( 18F)-radiolabeled slyrylpyridine tosylate precursor extracted from patent WO2010078370A1, example 1.5. AV-105 can synthesize 18F-radiolabeled compounds, which are used for positron emission tomography (PET) imaging of neurodegenerative diseases of the brain .
|
-
-
- HY-B0594R
-
|
|
Autophagy
Mitophagy
|
Cancer
|
|
Iohexol (Standard) is the analytical standard of Iohexol. This product is intended for research and analytical applications. Iohexol is a non-ionic, water-soluble contrast agent used as a reference marker for the determination of glomerular filtration rate (GFR) at the level of renal function. Iohexol can be used for contrast in myelography, computerized tomography (cisternography, ventriculography) and MicroCT imaging .
|
-
-
- HY-121810
-
|
|
Others
|
Others
|
|
LBT-999 is a phenyltropane derivative used for positron emission tomography (PET) exploration of the dopamine transporter (DAT). It has high affinity binding to DAT on rat striatal membranes and human postmortem brain slices in vitro, high uptake in the striatum in rat and baboon models in vivo, and its binding can be blocked by specific compounds.
|
-
-
- HY-125399
-
|
HBED-CC-PSMA
|
PSMA
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .
|
-
- HY-141464
-
|
Fmoc-Asn(Ac3AcNH-beta-Glc)-OH
|
Amino Acid Derivatives
|
Cancer
|
|
Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH (Fmoc-Asn(Ac3AcNH-beta-Glc)-OH) can be used in the synthesis of silicon-fluoride acceptor (SiFA) derivatized octreotate derivatives. SiFA-octreotate analogues, as tumor imaging agents, are useful tool for the research of positron emission tomography (PET) .
|
-
- HY-W422400
-
|
|
Biochemical Assay Reagents
|
Others
Cancer
|
|
Fluoroglutamine (2S,4R) is a fluorinated derivative of glutamine. As a substrate for various aminotransferases, Fluoroglutamine (2S,4R) can be used as a tracer for positron emission tomography (PET) imaging. Fluoroglutamine (2S,4R) is applied in the research fields of tumor metabolism and imaging .
|
-
- HY-111189
-
|
|
GlyT
|
Neurological Disease
|
|
GSK931145 is a glycine transporter 1 (GlyT1) inhibitor with anti-epileptic activity. GSK931145 exhibits a low minimum effective dose in the maximum electrical stimulation threshold test, indicating that it has a significant anti-epileptic effect. GSK931145 is also suitable as a positron emission tomography (PET) radioligand for quantifying the availability of glycine transporters in the living brain .
|
-
- HY-P9902A
-
|
MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)
|
PD-1/PD-L1
|
Cancer
|
|
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 .
|
-
- HY-161965
-
|
|
FAAH
|
Neurological Disease
|
|
MK-3168 (12C) is a FAAH inhibitor with IC50 values of 1.0, 5.5, 1.7 nM for human, rhesus, rat, respectively. MK-3168 shows good brain uptake and FAAH-specific signal. 11C MK-3168 can be used as FAAH PET tracer .
|
-
- HY-122607
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
DPA-714 is a high affinity translocator protein (TSPO) ligand (Ki=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. 18FDPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model .
|
-
- HY-100133A
-
|
|
Integrin
|
Cancer
|
|
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .
|
-
- HY-159602
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BET BD2-IN-3 (compound I-58) is an inhibitor of BET, targeting the BD2 domain of BET. BET BD2-IN-3 can be radiolabeled with [11C] for positron emission tomography (PET) imaging. BET [11C]BD2-IN-3 showed suitable biodistribution in peripheral organs and tissues in PET applications in mice .
|
-
- HY-169071S
-
|
|
Phosphodiesterase (PDE)
|
Others
|
|
ATX-1905 is a positron emission tomography (PET) tracer that demonstrates good autotaxin (ATX) binding specificity and achieves semiquantification of lung ATX expression levels, which are elevated in fibrotic lungs. ATX-1905 exhibits elevated uptake in Bleomycin (HY-108345)-induced pulmonary fibrosis (BPF) lungs. ATX-1905 is promising for research of idiopathic pulmonary fibrosis (IPF) .
|
-
- HY-162574
-
|
|
Cytochrome P450
|
Cancer
|
|
CYP11B2-IN-2 (Compound 10k) is an inhibitor for enzyme aldosterone synthase CYP11B2 with an IC50 of 0.3 nM. CYP11B2-IN-2 CYP11B-IN-2 is labeled with 18F and can be used as a positron emission tomography (PET) tracer for the diagnosis of primary aldosteronism .
|
-
- HY-167898
-
|
|
Amyloid-β
|
Neurological Disease
|
|
MeS-IMPY is a ligand of β-amyloid plaques. MeS-IMPY shows a high binding affinity to β-amyloid plaques extracted from Alzheimer's disease (AD) human brains or AD brain homogenates compared to IMPY (Ki=7.93 and 8.95 nM, respectively). [ 11C]MeS-IMPY is a potential radioligand for imaging β-amyloid plaques with positron emission tomography (PET) .
|
-
- HY-159108
-
|
|
c-Fms
|
Cardiovascular Disease
|
|
AZ683 is a potent and selective 3-amido-4-anilinoquinoline CSF1R inhibitor. AZ683 has high affinity for CSF1R (Ki=8 nM; IC50=6 nM). AZ683 has good oral bioavailability. [ 11C]AZ683 can be used as a positron emission tomography (PET) radiotracer for colony stimulating factor 1 receptor (CSF1R) .
|
-
- HY-164475
-
|
|
PARP
|
Cancer
|
|
PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting PARP-1 activity in cancer .
|
-
- HY-156102
-
|
|
Bcr-Abl
|
Neurological Disease
|
|
c-ABL-IN-5 is a selective c-Abl inhibitor with neuroprotective effects. c-ABL-IN-5 has blood-brain barrier penetrability, metabolic stability and good pharmacokinetic properties. When c-ABL-IN-5 is labeled with [18F] (compound [18F]3), it can be used as a tracer to evaluate disease-modifying efficacy by complementary positron emission tomography (PET). c-ABL-IN-5 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD) .
|
-
- HY-123446
-
|
|
Others
|
Neurological Disease
|
|
JNJ-42259152 is a phosphodiesterase 10A (PDE10A) positron emission tomography (PET) tracer that is specific for PDE10A activity. JNJ-42259152 can be dynamically scanned in healthy volunteers to assess its kinetic properties in the brain. The half-life of JNJ-42259152 in the blood is an average of 90 minutes. JNJ-42259152 has demonstrated reliable binding potential (BPND) in different target areas (such as the lentiform nucleus, caudate nucleus, ventral striatum, etc.), providing an important tool for studying neuropsychiatric diseases .
|
-
- HY-141637
-
|
2-Fluoro-2-deoxy-D-glucose; 2-Deoxy-2-fluoro-D-glucopyranose
|
Biochemical Assay Reagents
|
Others
|
|
2-Deoxy-2-fluoro-D-glucose, a radiolabeled glucose analog, is commonly used in medical imaging techniques such as positron emission tomography (PET) scans. FDG has unique chemical properties that allow it to be taken up by cells that actively metabolize glucose, such as cancer cells or inflamed tissue. Once absorbed, FDG emits positrons that can be detected in 2-Deoxy-2-fluoro-D-glucose scans, producing images that highlight areas of high metabolic activity in the body. This makes it a useful tool for diagnosing and monitoring a variety of diseases, including cancer and neurological disorders.
|
-
- HY-121659
-
|
|
PSMA
|
Cancer
|
|
DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor that can be used for small animal positron emission tomography (PET) imaging. DCFBC labeled with F 18 ([18F]DCFBC) can images in severe combined immunodeficient mice. [18F]DCFBC uptake is higher in PIP tumors, but almost absent in FLU tumors. [18F]DCFBC uptake is also high in the kidney and bladder, but the radioactivity washout time is shorter than that in PIP tumors. Indicating that [18F]DCFBC can specifically localize to PSMA+ expressing tumors and is applicable to the study of prostate cancer .
|
-
- HY-128890
-
|
|
ADC Linker
|
Cancer
|
|
DOTA-NHS-ester is a linker for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors .
|
-
- HY-13488
-
|
|
LRRK2
MNK
|
Neurological Disease
|
|
HG-10-102-01 is a highly potent, selective, and brain-penetrable LRRK2 inhibitor, with IC50 values of 20.3 and 3.2 nM against wild-type LRRK2 and LRRK2[G2019S], respectively. HG-10-102-01 also inhibits MNK2 and MLK1, with IC50 values of 0.6 and 2.1 μM. HG-10-102-01 can be used for Parkinson's disease (PD) research .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D2334
-
|
|
Dyes
|
|
AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .
|
| Cat. No. |
Product Name |
Type |
-
- HY-100133A
-
|
|
Chelators
|
|
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .
|
-
- HY-141637
-
|
2-Fluoro-2-deoxy-D-glucose; 2-Deoxy-2-fluoro-D-glucopyranose
|
Carbohydrates
|
|
2-Deoxy-2-fluoro-D-glucose, a radiolabeled glucose analog, is commonly used in medical imaging techniques such as positron emission tomography (PET) scans. FDG has unique chemical properties that allow it to be taken up by cells that actively metabolize glucose, such as cancer cells or inflamed tissue. Once absorbed, FDG emits positrons that can be detected in 2-Deoxy-2-fluoro-D-glucose scans, producing images that highlight areas of high metabolic activity in the body. This makes it a useful tool for diagnosing and monitoring a variety of diseases, including cancer and neurological disorders.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10734
-
|
|
Peptides
|
|
|
NODAGA-RGD is a peptide that can be radiolabeled and used as a radiotracer for positron emission tomography (PET) diagnosis .
|
-
- HY-106244
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-106244A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-153549
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Others
|
|
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10220
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Biochemical Assay Reagents
|
Others
|
|
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography . NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10744
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5053
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Integrin
|
Cancer
|
|
Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α?β? selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5413
-
|
|
Peptides
|
Others
|
|
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9902A
-
|
MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)
|
PD-1/PD-L1
|
Cancer
|
|
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 .
|
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0594S
-
|
|
|
Iohexol-d5 is deuterium labeled Iohexol. Iohexol is a radiographic contrast agent and can be applied for myelography, computerized tomography (cisternography, ventriculography) and MicroCT imaging in vivo[1].
|
-
-
- HY-169071S
-
|
|
|
ATX-1905 is a positron emission tomography (PET) tracer that demonstrates good autotaxin (ATX) binding specificity and achieves semiquantification of lung ATX expression levels, which are elevated in fibrotic lungs. ATX-1905 exhibits elevated uptake in Bleomycin (HY-108345)-induced pulmonary fibrosis (BPF) lungs. ATX-1905 is promising for research of idiopathic pulmonary fibrosis (IPF) .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
